Cell Source Stock Price, News & Analysis
Company Description
Cell Source (OTC Link: CLCS) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $57.1M.
CLCS stock has gained 159.3% over the past year. Shares last traded at $0.8400.
On a trailing twelve-month basis, Cell Source and diluted earnings per share of $-0.14.
This page provides a comprehensive overview of CLCS stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Cell Source (CLCS) stock last traded at $0.8400, down 1.51% from the previous close. Over the past 12 months, the stock has gained 159.3%. At a market capitalization of $57.1M, CLCS is classified as a micro-cap stock with approximately 67.9M shares outstanding.
Latest News
Cell Source has 6 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 2 with negative movement. Key topics include clinical trial, management. View all CLCS news →
SEC Filings
Cell Source has filed 1 recent SEC filing, including 1 Form 10-K. The most recent filing was submitted on April 6, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CLCS SEC filings →
Financial Highlights
Diluted earnings per share stood at $-0.14.
Upcoming Events
Convertible notes maturity
Cell Source has 1 upcoming scheduled event. The next event, "Convertible notes maturity", is scheduled for June 17, 2026 (in 51 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the CLCS stock price.
Short Interest History
Short interest in Cell Source (CLCS) currently stands at 5.4 thousand shares, down 40.6% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has increased by 104.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Cell Source (CLCS) currently stands at 1.1 days, down 65.3% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 7.9 days.
CLCS Company Profile & Sector Positioning
Cell Source (CLCS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing CLCS often look at related companies in the same sector, including Oncotelic Therapeutics Inc (OTLC), Finch Therapeutics Group, Inc. (FNCH), Biomind Labs Inc (BMNDF), ACCUSTEM SCIENCES INC (ACUT), and Pharmather Holdings Ltd (PHRRF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CLCS's relative position within its industry.